- Home
- STEC vs RVPH Comparison
STEC vs RVPH Comparison
Compare STEC & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- RVPH
- Stock Information
- Founded
- STEC 2006
- RVPH 2006
- Country
- STEC Hong Kong
- RVPH United States
- Employees
- STEC N/A
- RVPH N/A
- Industry
- STEC
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- RVPH Health Care
- Exchange
- STEC NYSE
- RVPH Nasdaq
- Market Cap
- STEC 63.8M
- RVPH 26.6M
- IPO Year
- STEC 2021
- RVPH N/A
- Fundamental
- Price
- STEC $0.72
- RVPH $0.47
- Analyst Decision
- STEC
- RVPH Strong Buy
- Analyst Count
- STEC 0
- RVPH 5
- Target Price
- STEC N/A
- RVPH $9.00
- AVG Volume (30 Days)
- STEC 12.8K
- RVPH 3.2M
- Earning Date
- STEC 08-05-2025
- RVPH 08-13-2025
- Dividend Yield
- STEC N/A
- RVPH N/A
- EPS Growth
- STEC N/A
- RVPH N/A
- EPS
- STEC N/A
- RVPH N/A
- Revenue
- STEC $10,672,000.00
- RVPH N/A
- Revenue This Year
- STEC $9,392.20
- RVPH N/A
- Revenue Next Year
- STEC N/A
- RVPH N/A
- P/E Ratio
- STEC N/A
- RVPH N/A
- Revenue Growth
- STEC N/A
- RVPH N/A
- 52 Week Low
- STEC $0.20
- RVPH $0.30
- 52 Week High
- STEC $3.25
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- STEC 38.03
- RVPH 47.55
- Support Level
- STEC $0.70
- RVPH $0.38
- Resistance Level
- STEC $0.80
- RVPH $0.53
- Average True Range (ATR)
- STEC 0.08
- RVPH 0.04
- MACD
- STEC 0.00
- RVPH 0.03
- Stochastic Oscillator
- STEC 34.03
- RVPH 59.87
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. It has two revenue segments Wealth management service and Asset management service. Key revenue is generated from Wealth management service.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.